Micafungin Pharmazac (Micafungin)

Micafungin is an echinocandin antifungal indicated for several serious Candida infections.

• Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections.
• Candida esophagitis: resolves esophageal Candida lesions and associated symptoms.
• Candida peritonitis: treats intra‑abdominal Candida infections.
• Prophylaxis in hematopoietic stem cell transplant patients: prevents invasive Candida disease during periods of severe immunosuppression.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell death, while having minimal effect on human cells that lack this pathway.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature during infusion.
• Nausea: mild gastrointestinal discomfort.
• Headache: occasional mild to moderate headache.
• Infusion‑related reactions: flushing, erythema, or mild hypotension.

Serious or Rare Side Effects

• Hepatic dysfunction: elevated transaminases or rare liver failure.
• Severe hypersensitivity: anaphylaxis, bronchospasm, or angioedema.
• Renal impairment: acute kidney injury in susceptible patients.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: rare severe skin reactions.

Before initiating Micafungin therapy, clinicians should consider several safety measures.

• Liver function monitoring: assess baseline enzymes and repeat during treatment.
• Renal function assessment: evaluate creatinine clearance, especially in patients with pre‑existing kidney disease.
• Hypersensitivity screening: inquire about prior allergic reactions to echinocandins.
• Caution in hepatic disease: adjust therapy if significant liver impairment is present.
• Use in special populations: consider age‑related dosing adjustments for pediatric or elderly patients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its concentration or the partner drug's effect.

Major Interactions (Avoid)

• Rifampin: induces metabolism, markedly reducing micafungin exposure.
• Cyclosporine: inhibits clearance, leading to increased micafungin levels and potential toxicity.
• Strong CYP3A4 inducers (e.g., carbamazepine): may lower micafungin concentrations.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin levels; monitor for adverse effects.
• Warfarin: potential alteration of INR; check coagulation parameters regularly.
• Statins (e.g., simvastatin): possible increased risk of myopathy; observe muscle symptoms.